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Abstract
Human infections caused by Weissella confusa are rarely reported. Ten patients with bacteraemia caused by W. confusa who were trea-
ted at a tertiary-care hospital in Taiwan during 1997–2007 were studied. All isolates were initially misidentiﬁed as various Lactobacillus
and Leuconostoc species by two commercial automated identiﬁcation methods, and were conﬁrmed to be W. confusa by 16S rRNA
sequencing analysis. MICs of these isolates for ten antimicrobial agents were determined by the agar dilution method. The characteris-
tics of these patients included underlying malignancy (n = 4), presence of a central catheter (n = 6), surgery within the previous
3 months (n = 4) and concomitant polymicrobial bacteraemia (n = 5, 50%). Mortality was directly attributed to bacteraemia in two
patients. All isolates exhibited high trimethoprim–sulphamethoxazole and ceftazidime MICs (‡128 mg/L) and were inhibited by linezolid,
daptomycin, ceftobiprole and tigecycline at 4, 0.12, 2 and 0.12 mg/L, respectively. In conclusion, W. confusa should be included in the list
of organisms causing bacteraemia in immunocompromised hosts. Novel antibiotics, including daptomycin, moxiﬂoxacin, doripenem and
tigecycline, exert good activity against W. confusa.
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Introduction
Isolates of Weissella species, ﬁrst identiﬁed in 1993, are
Gram-positive, catalase-negative coccobacilli that are intrinsi-
cally resistant to vancomycin [1,2]. Bacteraemia caused by
Weissella species in humans is extremely rare, and its
pathogenic role has not been established [3–5]. Isolates of
Weissella species retrieved from blood culture are easily
misidentiﬁed as Lactobacillus and Leuconostoc species by tradi-
tional or commercial phenotypic identiﬁcation methods, and
are often considered to be contaminants [3,6]. Among the
different Weissella species, Weissella confusa (basonym Lacto-
bacillus confusus) is the most commonly recovered species
from clinical samples, and has been linked to infective
endocarditis [3,4]. W. confusa has been detected in various
samples, including fermented foods, sugar cane, milk, otitis
samples and human faeces [1,7]. The clinical signiﬁcance of
Weissella bacteraemia remains unclear, but the organism has
been frequently isolated in patients with complex medical
conditions and immunocompromised status [2,3,5].
The aim of this study was to investigate the clinical and
microbiological characteristics of patients with W. confusa
bacteraemia. All isolates were conﬁrmed to the species level
by 16S RNA sequencing analysis, and the results were com-
pared with those obtained with two commercial automated
identiﬁcation methods. Susceptibilities of these W. confusa
isolates to various antibiotics were also determined.
Materials and Methods
Bacterial isolates, patients and setting
This study was conducted at National Taiwan University
Hospital, a 2900-bed tertiary-care centre in northern Taiwan.
A total of 43 blood isolates of Gram-positive, catalase-
negative, vancomycin-resistant coccobacilli, with negative
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reactions for pyrrolidonyl arylamidase and leucine aminopepti-
dase, collected from the Clinical Microbiology Laboratory of
the hospital from 1997 to 2007 were studied. These isolates
were identiﬁed as either Lactobacillus or Leuconostoc species by
traditional or commercial automated identiﬁcation systems [8].
Clinical characteristics
A standardized case record form was used to collect demo-
graphic and clinical data, including patients’ age, gender and
underlying status, the presence or absence of central vascu-
lar access, surgical procedure received, initial clinical presen-
tation, and empirical antibiotic usage and glycopeptide usage
within 3 months prior to the acquisition of bacteraemia.
Disease severity was evaluated with the Pittsburgh bacter-
aemia score and modiﬁed APACHE II (Acute Physiology and
Chronic Health Evaluation) scores calculated within 8 h after
positive blood cultures were obtained [9]. The modiﬁed
APACHE II score assigned zero points to the items ‘PaO2’
and ‘pH’ if the data of the two variables were unavailable
under the condition that the attending physicians did not
perform arterial blood gas analysis [10]. Crude mortality
was calculated on day 30 and day 60 as the main patient
outcome.
Species identiﬁcation by commercial automated methods
All 43 isolates from patients with bacteraemia were repeatedly
identiﬁed with the identiﬁcation panels (SMIC/ID-100) of the
Phoenix Automated Microbiology System (Becton Dickinson
Diagnostic, Sparks, MD, USA) and the Vitek 2 system (bio-
Merieux,Marcy l’Etoile, France) forGram-positive identiﬁcation.
The last updated versions of the Phoenix (software ver-
sion 5.02H/4.11B, 20 May 2010) and Vitek 2 (Version 4.02PC,
July 2010) databaseswereobtained fromthemanufacturers.
16S rRNA gene sequencing analysis
The 16S rRNA sequencing analysis was performed for the 43
blood isolates initially identiﬁed as Lactobacillus and Leuconos-
toc species. Partial sequencing of the 16S rRNA gene up to
1475 bp was performed for species identiﬁcation of all iso-
lates, with the following primers: forward, 5¢-AGAGTTTG
ATCCTGGCTCAG-3¢; and reverse, 5¢-GGTTACCTTGT
TACGACTT-3¢ [8]. The results were compared with
published sequences in the GenBank database, using the
BLASTN algorithm. The closest matches and GenBank acces-
sion number were obtained. Leuconostoc lactis ATCC 19256
was used as the control strain in each test.
Antimicrobial susceptibility testing
MICs for ampicillin, ampicillin–sulbactam, amoxicillin–clavulan-
ic acid, ceftazidime, trimethoprim–sulphamethoxazole and
vancomycin (Sigma, St Louis, MO, USA), moxiﬂoxacin (Bayer,
West Haven, CT, USA), azithromycin, linezolid, piperacillin–
tazobactam and tigecycline (Pﬁzer, New York, NY, USA),
meropenem (Sumitomo, Osaka, Japan), doripenem (Shionogi,
Tokyo, Japan), ceftobiprole (Johnson & Johnson, Raritan, NJ,
USA) and daptomycin (Cubist, Lexington, MA, USA) were
determined with the broth microdilution method, with horse
blood supplementation according to CLSI guidelines [11].
Cation-adjusted broth containing 50 mg/L calcium was used
for daptomycin susceptibility testing [12]. Staphylococcus aur-
eus ATCC 29213, Enterococcus faecalis ATCC 29212 and
Streptococcus pneumoniae ATCC 49619 were used as quality
control strains.
Results
Species identiﬁcation
Among the 43 isolates, ten were identiﬁed as W. confusa by
16S rRNA gene sequencing analysis. Among the other 33
isolates, 15 were identiﬁed as L. lactis, three as Leuconostoc
citreum, one as Leuconostoc mesenteroides, one as Leuconostoc
pseudomesenteroides, three as Lactobacillus fermentum, eight as
Lactobacillus sallivarius, one as Pediococcus acidilactici and one as
Streptococcus anginosus. These 33 isolates were also identiﬁed
with the same 16S rRNA gene sequencing analysis with at
least 99% maximal identity (data shown elsewhere).
The results of the identiﬁcation of the ten isolates with
the Phoenix Automated Microbiology System and the Vitek 2
system are presented in Table 1. Half of the ten isolates
were misidentiﬁed as L. mesenteroides by the Phoenix system.
Two isolates were identiﬁed as Streptococcus bovis II, one as
L. lactis and one as Staphylococcus hominis; one pathogen was
not identiﬁed. The Vitek 2 system categorized four of the
ten species as L. pseudomesenteroides. Three of these were
unidentiﬁed organisms, two were Pediococcus pentosaceus and
one was Streptococcus agalactiae/Streptococcus equinus. None
of the isolates could be correctly identiﬁed as W. confusa by
the Phoenix Automated Microbiology System or by the
Vitek 2 system. Signiﬁcant discrepancy also exists within the
two commercial identiﬁcation systems, as only two isolates
were correctly identiﬁed to the genus level and none was
correctly identiﬁed to the species level. The discrepancy pos-
sibly resulted from inherent limitations of these identiﬁcation
systems and different times of database development.
Characteristics of patients
The clinical characteristics of the ten patients with W. con-
fusa bacteraemia are shown in Table 2 and summarized in
Table 3. Of the ten patients, six were female. The mean age
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of the patients was 56.6 years, and all except one were
adults. Four patients had underlying malignancy, including
two with haematological malignancy and two with solid
organ cancer. Other factors considered to be indicative of
immunocompromised status included steroid usage (n = 3),
chronic renal insufﬁciency (deﬁned as creatinine level >2 mg/
dL) (n = 3) and diabetes mellitus (n = 1). Six patients had
central venous catheters or Port-A-Cath implantations at the
time of bacteraemia onset. One paediatric patient had a
peripheral venous line implanted and was receiving total par-
enteral nutrition. Four patients had undergone surgery within
the past 3 months.
Fever remained the most common symptom of bactera-
emia (80%). Gastrointestinal symptoms, including abdominal
pain, vomiting or diarrhoea, were present in four patients.
The mean Pitt bacteraemia score was 2.5, and the mean
APACHE II score was 19.9. Eight of the ten patients had
hospital-acquired bacteraemia. The mean duration of hospi-
talization was 55.4 days (range 6–257 days). The other two
patients were categorized as having healthcare-associated
bacteraemia.
All ﬁve patients had concomitant polymicrobial infection.
The concomitant pathogens isolated included Acinetobacter
baumannii, Enterobacter cloacae, E. faecalis, Candida albicans,
Bacillus species, methicillin-resistant S. aureus, Escherichia coli,
Chryseobacterium indologenes and Enterobacter aerogenes.
Among the ﬁve monomicrobial bacteraemias, three were
detected in more than two blood culture sets, and the
remaining two had positive cultures in one blood culture set
(two bottles).
Nine patients received initial broad-spectrum b-lactam
antibiotics (including ampicillin–sulbactam in two patients,
amoxicillin–clavulanate in three, ceftazidime in three and
cefepime in one). One patient received no antibiotics at all.
One patient received a combination of four antibiotics:
trimethoprim–sulphamethoxazole, vancomycin, ciproﬂoxacin
and ceftazidime. Notably, three patients received vancomycin
as an empirical antibiotic, which was not effective against
W. confusa. Four patients had received vancomycin in the
previous 3 months. Among the eight patients who survived
until initial culture was available, antibiotics were adjusted to
ampicillin–sulbactam in two patients, piperacillin–tazobactam
in one patient, amoxicillin–clavulanate in one patient, pipera-
cillin–tazobactam in one patient, penicillin in one patient and
ciproﬂoxacin in one patient; no antibiotics were given to one
patient.
Six of the eight patients who initially had febrile symptoms
achieved defeverence within 72 h. The overall 14-day, 30-day
and 60-day mortality rates were 30%, 40% and 50%, respec-
tively. Mortality was directly attributed to bacteraemia in
two patients. Only four patients survived until discharge.
Antimicrobial susceptibilities
Table 4 shows the MICs of the ten isolates for 15 antimicrobial
agents. The ranges of MICs were as follows: 0.5–1 mg/L for
ampicillin, 0.5–2 mg/L for ceftobiprole, 2–4 mg/L for linezolid,
1–16 mg/Lfor meropenem, 0.5–16 mg/L for doripenem, 0.25–
0.5 mg/L for moxiﬂoxacin, 0.12–0.12 mg/L for azithromycin,
0.03–0.12 mg/L for linezolid, 0.03–0.12 mg/L for daptomycin,
‡128 mg/L for trimethoprim–sulphamethoxazole, ‡128 mg/L
for ceftazidime, 4–8 mg/L for piperacillin–tazobactam, 4–
16 mg/L for ampicillin–sulbactam, 0.5–8 mg/L for amoxicillin–
clavulanate, and >64 mg/L for vancomycin.
Discussion
Since the reclassiﬁcation of L. pseudomesenteroides as a mem-
ber of the Weissella genus because of its distinct 16S rRNA
phylogenetic proﬁle [1], more than ten species (including
W. confusa, previously Lactobacillus confusus) have been
included in this novel genus. Invasive Weissella species infec-
tion is extremely rare. Most reports include W. confusa
bloodstream infection, with endocarditis being the focus of
TABLE 1. Species identiﬁcation of the
ten isolates by different methodsIsolate no.
16S rRNA sequencing
(maximal identity, %)
Phoenix system
(% identity) Vitek 2 system (% identity)
1 Weissella confusaa (100) Leuconostoc mesenteroides (90) Pediococcus pentosaceus (86)
2 W. confusa (100) L. mesenteroides (99) Leuconostoc pseudomesenteroides (86)
3 W. confusa (99) Streptococcus bovis II (99) Unidentiﬁed organism
4 W. confusa (100) L. mesenteroides (96) Streptococcus agalactiae/
Streptococcus equinus (86)
5 W. confusa (100) Staphylococcus hominis (99) L. pseudomesenteroides (92)
6 W. confusa (100) L. mesenteroides (90) L. pseudomesenteroides/
Leuconostoc citreum (92)
7 W. confusa (99) L. mesenteroides (99) P. pentosaceus (86)
8 W. confusa (100) Unidentiﬁed organism Unidentiﬁed organism
9 W. confusa (99) Leuconostoc lactis (99) L. pseudomesenteroides/L. lactis (86)
10 W. confusa (99) Streptococcus bovis II (90) Unidentiﬁed organism
aGenBank accession number of W. confusa, GU138614.1.
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infection [3–5]. Correct identiﬁcation of Weissella species
cannot be achieved by commercial phenotypic identiﬁcation
methods [3]. Modern molecular techniques, including multi-
plex PCR, restriction of internal spacer region-ampliﬁed frag-
ments, genus-speciﬁc PCR analysis and 16S rRNA gene
sequencing, have been described for the identiﬁcation of Leu-
conostoc and Weissella species [6,13–15].
In a comparison with two commercial automated systems,
W. confusa species were often misidentiﬁed as Leuconostoc
species, followed by P. pentosaceus and Streptococcus bovis II.
Given the fact that ten of 43 blood isolates of Gram-positive,
catalase-negative and vancomycin-resistant coccobacilli
turned out to be W. confusa by the 16S rRNA gene sequenc-
ing method, the actual incidence of W. confusa bacteraemia
was undoubtedly underestimated. Matrix-assisted laser
desorption ionization time-of-ﬂight mass spectrometry is
increasingly being shown to be a fast, cost-effective and accu-
rate method for the routine identiﬁcation of bacterial iso-
lates and Gram-negative isolates causing bacteraemia,
including W. confusa [16–18]. Matrix-assisted laser desorption
ionization time-of-ﬂight mass spectrometry should be consid-
ered as a potential alternative method for the correct identi-
ﬁcation of this pathogen [18].
W. confusa has been reported to be a pathogenic microor-
ganism in primates (Cercopithecus mona) [19]. For human
beings, there are only three formal case reports on W. con-
fusa bacteraemia in the English-language literature. One case
was a 46-year-old male with a history of abdominal aortic
dissection status after repair, complicated by ischaemic
bowel, who developed concomitant Klebsiella pneumoniae and
W. confusa bacteraemia. No focus of infection could be iden-
tiﬁed, and the patient recovered after piperacillin–tazobactam
therapy [5]. Infective endocarditis was identiﬁed as a focus of
infection in the other two patients. One patient was a
49-year-old male with a diagnosis of W. confusa infectiveT
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TABLE 3. Comparison of clinical characteristics of 60-day
survivors and non-survivors of Weissella confusa bacteraemia
All
(n = 10)
Survivors
at 60 days
(n = 5)
Non-survivors
at 60 days
(n = 5)
Male/female 4/6 3/2 1/4
Mean age (years) 56.6 43.8 69.4
Overall malignancy, no. (%) 4 (40) 1 (20) 3 (60)
Prior chemotherapy
within 3 months, no. (%)
3 (30) 1 (20) 2 (40)
Presence of central
vascular catheter, no. (%)
6 (60) 2 (40) 4 (80)
Surgery within 3 months, no. (%) 4 (40) 3 (60) 1 (20)
Hospitalization days prior
to acquisition of bacteraemia
44.4 56.4 32.4
Mean Pitt bacteraemia score 2.5 1.4 3.6
Concomitant polymicrobial
bacteraemia (%)
5 (50) 2 (40) 3 (60)
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endocarditis. This patient died 4 days after discharge,
without any antibiotic treatment, and autopsy examination
showed septic emboli with bacterial colonies in multiple
organs [4]. The third patient underwent valve replacement
followed by prolonged antibiotic usage, and eventually recov-
ered [3].
The common features of patients in this study included
the presence of underlying immunocompromised status, cen-
tral catheter use and concomitant polymicrobial bacteraemia.
Malignancy was the most common factor associated with
immunocompromised status and also signiﬁed complicated
medical status. Three patients had chemotherapy in the
3 months prior to bacteraemia onset, and this might also
have predisposed these patients to having impaired immune
status. Breakdown of the gastrointestinal mucosal barrier
under conditions of abdominal surgery might serve as a por-
tal of entry for W. confusa. Six patients in this series either
had gastrointestinal symptoms at time of bacteraemia or had
undergone abdominal surgery in the previous 3 months.
Among the remaining four patients, two had received che-
motherapy within the previous 3 months, causing varying
degrees of mucositis.
The portal of entry of W. confusa among our patients
remained unclear. W. confusa was also found in fermented
foods, sugar cane, milk and carrot juice [1,7,20,21]. W. con-
fusa has also been detected in clinical samples of dog faeces,
human faeces, peritoneal ﬂuids and the abdominal walls of
patients [2,7,22]. Furthermore, Weissella cibria, the species
that is most closely taxonomically related to W. confusa, was
detected in traditional Taiwanese fermented foods (suan-tsai,
fu-tsai and yang-dong-gua) [23,24]. Skin defect resulting from
central vascular catheter implementation was considered to
be the portal of entry for Leuconostoc species [25,26]. Up to
60% of our patients had a central vascular catheter at the
time of bacteraemia onset; however, none of the catheter
tips gave a positive cultures for W. confusa. Furthermore, half
of our patients had polymicrobial bacteraemia, indicating that
gastrointestinal mucosal breakdown might be another proba-
ble route of entry for W. confusa resulting in bacteraemia.
The pathogenic role of Weissella species remained unclear
in this study. Five of our patients had W. confusa monomicro-
bial bacteraemia. Four of these patients were febrile, and for
three, the organism was grown in at least two sets of blood
cultures. The mean Pitt bacteraemia score was 1.4 (range
0–2). The severity of polymicrobial bacteraemia did not differ
signiﬁcantly from that of monomicrobial bacteraemia.
The antimicrobial susceptibilities of W. confusa are not
well understood. Low MICs of penicillin (0.38 mg/L), ampicil-
lin (0.5 mg/L), imipenem (0.06 mg/L), erythromycin (0.13 mg/
L), clindamycin (0.06 mg/L) and ciproﬂoxacin (0.5 mg/L) were
found in a previous study [27]. High-level resistance to
co-trimoxazole (>32 mg/L), metronidazole (>256 mg/L),
vancomycin (>256 mg/L) and teicoplanin (>256 mg/L) was
also reported [27]. In this study, we further demon-
strated the presence of high-level resistance to ceftazidime
(MIC ‡128 mg/L). Amoxicillin–clavulanate, ampicillin–sulbac-
tam, piperacillin–tazobactam, daptomycin, moxiﬂoxacin,
doripenem and tigecycline exerted good in vitro activity
against the W. confusa isolates tested. However, the in vitro
activities of linezolid, meropenem and cefobiprole against the
isolates tested varied. It is also noteworthy that three
patients who received cephalosporins (ceftazidime in two
and cefepime in one) as initial antibiotics had poor progno-
ses. In addition to penicillin, ampicillin, imipenem, clindamy-
cin, erythromycin, moxiﬂoxacin, doripenem, daptomycin and
tigecycline may be considered as alternative antimicrobial
agents for the treatment of W. confusa bacteraemia.
Vancomycin usage may alter the intestinal ﬂora, and is
considered to be a possible mechanism of Lactobacillus trans-
location [28,29]. Four of our patients had previously used
vancomycin. Two patients had previously used metronida-
zole. The use of vancomycin and metronidazole, to which
TABLE 4. Antimicrobial susceptibilities of ten blood isolates of Weissella confusa according to the agar dilution method
Isolate no.
MIC (mg/L)
AM SAM AMC CAZ CBP TZP MEM DOR Moxi VA DAP LIN AZI SXT TGC
1 0.5 8/4 0.5/0.25 128 1 4/4 1 0.5 0.5 >64 0.03 2 0.12 128 0.06
2 0.5 8/4 0.5/0.25 >128 1 4/4 1 0.5 0.5 >64 0.03 4 0.12 >128 0.12
3 0.5 8/4 0.5/0.25 >128 0.5 8/4 2 0.5 0.25 >64 0.12 2 0.12 >128 0.06
4 0.5 8/4 0.5/0.25 >128 2 8/4 2 2 0.25 >64 0.03 2 0.12 128 0.03
5 0.5 8/4 0.5/0.25 >128 2 4/4 8 8 0.5 >64 0.03 2 0.12 >128 0.06
6 0.5 8/4 0.5/0.25 >128 2 4/4 16 8 0.25 >64 0.12 4 0.12 16 0.06
7 0.5 4/2 0.5/0.25 >128 1 4/4 1 0.5 0.25 >64 0.03 2 0.12 128 0.06
8 0.5 8/4 0.5/0.25 >128 1 4/4 1 0.5 0.25 >64 0.03 2 0.12 128 0.03
9 1 16/8 8/4 >128 2 4/4 16 16 0.5 >64 0.12 4 0.12 >128 0.12
10 0.5 8/4 0.5/0.25 >128 0.5 4/4 1 0.5 0.25 >64 0.03 2 0.12 >128 0.06
AM, ampicillin; AMC, amoxicillin–clavulanate; AZI, azithromycin; CAZ, ceftazidime; CBP, ceftobiprole; DAP, daptomycin; DOR, doripenem; LIN, linezolid; MEM, meropenem;
Moxi, moxiﬂoxacin; SAM, ampicillin–sulbactam; SXT, trimethoprim–sulphamethoxazole; TGC, tigecycline; TZP, piperacillin–tazobactam; VA, vancomycin.
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the Weissella species are resistant, may be considered as a
risk factor for Weissella bacteraemia.
In conclusion, W. confusa should be included in the list of
organisms causing bacteraemia in immunocompromised
hosts. The most probable portal of entry is surgery-related
or chemotherapy-related compromise of the gastrointestinal
mucosal barrier. An inherent problem with commercial phe-
notypic identiﬁcation is outdated databases, preventing accu-
rate identiﬁcation, and 16S rRNA gene sequencing is able to
identify W. confusa. Novel antibiotics, including daptomycin,
moxiﬂoxacin, doripenem and tigecycline, exert good in vitro
activity against W. confusa. Clinicians should keep in mind
that when growth of Gram-positive cocci is found in the
blood cultures of hospitalized susceptible hosts, vancomycin-
resistant species, including W. confusa, should be considered.
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